Statement of Changes in Beneficial Ownership (4)

Date : 01/07/2020 @ 11:31PM
Source : Edgar (US Regulatory)
Stock : Horizon Therapeutics Public Limited Company (HZNP)
Quote : 36.06  0.37 (1.04%) @ 1:00AM
After Hours
Last Trade
Last $ 36.06 ◊ 0.00 (0.00%)

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Kent Jeff
2. Issuer Name and Ticker or Trading Symbol

Horizon Therapeutics Public Ltd Co [ HZNP ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
See remarks
(Last)          (First)          (Middle)

C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
3. Date of Earliest Transaction (MM/DD/YYYY)

1/3/2020
(Street)

DUBLIN, L2 4
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 1/5/2020  M  14873 A (1)121988 D  
Ordinary Shares 1/5/2020  F  6776 D$36.10 115212 D  
Ordinary Shares 1/7/2020  S(2)  3545 D$36.50 (3)111667 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units (RSU)  (1)1/3/2020  A   29027     (4) (4)Ordinary Shares 29027 $0.00 29027 D  
Restricted Stock Units (RSU)  (1)1/5/2020  M     6700   (5) (5)Ordinary Shares 6700 $0.00 6700 D  
Restricted Stock Units (RSU)  (1)1/5/2020  M     8173   (6) (6)Ordinary Shares 8173 $0.00 16348 D  

Explanation of Responses:
(1) Each RSU represents a contingent right to receive one ordinary share of the Issuer.
(2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 23, 2019.
(3) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.51 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(4) The RSU's vest 1/3rd annually on each anniversary of January 5, 2020.
(5) The RSU's vest 1/3rd annually on each anniversary of January 5, 2018.
(6) The RSU's vest 1/3rd annually on each anniversary of January 5, 2019.

Remarks:
Officer Title: SVP, Head of Medical Affairs & Outcomes Research.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Kent Jeff
C/O HORIZON THERAPEUTICS PLC
CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
DUBLIN, L2 4


See remarks

Signatures
/s/ Miles W. McHugh, Attorney-in-Fact1/7/2020
**Signature of Reporting PersonDate

Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart

1 Year : From Feb 2019 to Feb 2020

Click Here for more Horizon Therapeutics Pub... Charts.

Horizon Therapeutics Pub... (NASDAQ:HZNP)
Intraday Stock Chart

Today : Wednesday 19 February 2020

Click Here for more Horizon Therapeutics Pub... Charts.

Latest HZNP Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.